Ming Sheng Yu

US Patent:

20110142815, Jun 16, 2011

Filed:

Jan 4, 2010

Appl. No.:

12/667687

Inventors:

Ming YU - Los Angeles CA, US

International Classification:

A61K 31/41
A61K 38/43
A61K 31/7052
C12N 5/09
A61P 35/00

US Classification:

424 941, 514381, 514 44 A, 435375

Abstract:

This invention describes methods and pharmaceutical compositions for combinational cancer treatments that are capable of inducing JNK phosphorylation and induce programmed cell death. It also identified genes as target for anti-cancer drug development and enhancement of the chemotherapeutic drug effect for the treatment of cancer. This invention points to a novel method and principle for a new avenue of developing more efficient and low or non cytotoxic cancer treatment.

US Patent:

20110319378, Dec 29, 2011

Filed:

Jun 3, 2011

Appl. No.:

13/153345

Inventors:

Michael David BARTBERGER - Sherman Oaks CA, US
Ana GONZALEZ BUENROSTRO - San Mateo CA, US
Hilary Plake BECK - San Carlos CA, US
Xiaoqi CHEN - Palo Alto CA, US
Richard Victor CONNORS - Pacifica CA, US
Jeffrey DEIGNAN - San Francisco CA, US
Jason DUQUETTE - Millbrae CA, US
John EKSTEROWICZ - San Francisco CA, US
Benjamin FISHER - San Mateo CA, US
Brian Matthew FOX - Brisbane CA, US
Jiasheng FU - Foster City CA, US
Zice FU - Foster City CA, US
Felix GONZALEZ LOPEZ DE TURISO - San Mateo CA, US
Michael GRIBBLE, JR. - San Francisco CA, US
Darin James GUSTIN - Half Moon Bay CA, US
Julie Anne HEATH - Orinda CA, US
Xin HUANG - Wellesley MA, US
Xianyun JIAO - Belmont WA, US
Michael G. JOHNSON - San Francisco CA, US
Frank KAYSER - San Francisco CA, US
David John KOPECKY - San Francisco CA, US
Sujen LAI - Burlingame CA, US
Yihong LI - Millbrae CA, US
Zhihong LI - Millbrae CA, US
Jiwen LIU - Foster City CA, US
Jonathan Dante LOW - Tarzana CA, US
Brian Stuart LUCAS - San Francisco CA, US
Zhihua MA - Foster City CA, US
Lawrence McGEE - Pacifica CA, US
Joel McINTOSH - Pacifica CA, US
Dustin McMINN - Pacifica CA, US
Julio Cesar MEDINA - San Carlos CA, US
Jeffrey Thomas MIHALIC - San Francisco CA, US
Steven Howard Olson - Foster City CA, US
Yosup REW - Foster City CA, US
Philip Marley ROVETO - San Francisco CA, US
Daqing SUN - Foster City CA, US
Xiaodong WANG - Millbrae CA, US
Yingcai WANG - Millbrae CA, US
Xuelei YAN - Foster City CA, US
Ming YU - Foster City CA, US
Jiang ZHU - Palo Alto CA, US

Assignee:

AMGEN INC. - Thousand Oaks CA

International Classification:

A61K 31/451
C07D 413/06
A61K 31/5377
C07D 401/06
A61K 31/454
C07D 417/06
A61K 31/541
A61K 31/4545
C07D 413/12
C07D 471/10
A61K 31/438
C07D 409/04
A61K 31/4535
A61K 31/496
C07D 279/02
C07D 498/08
A61K 31/5386
A61K 31/549
C07D 498/16
A61K 31/437
A61P 35/00
C07D 211/40

US Classification:

5142102, 546221, 514327, 544130, 5142355, 546208, 514326, 544 582, 5142278, 546209, 546194, 514318, 546216, 5142372, 546 17, 514278, 546213, 544360, 51425312, 544 3, 5142222, 544105, 5142305, 544 11, 5142228, 546 90, 514291

Abstract:

The present invention provides MDM2 inhibitor compounds of Formula I,

US Patent:

20170081662, Mar 23, 2017

Filed:

Sep 26, 2016

Appl. No.:

15/275863

Inventors:

Ming Yu - Los Angeles CA, US

International Classification:

C12N 15/113

Abstract:

This invention points to biological molecules and/or sequences that can be used as target for designing drug for treating cancer. This invention also points to biological sequences that can be used to target those molecules as a mean to treat cancer.

US Patent:

20140163088, Jun 12, 2014

Filed:

Jan 9, 2014

Appl. No.:

14/151539

Inventors:

Ming YU - Los Angeles CA, US

International Classification:

A61K 31/713
A61K 45/06
A61K 31/47
C07D 257/04
A61K 31/41

US Classification:

514 44 A, 548252, 514381

Abstract:

This invention describes methods and pharmaceutical compositions for combinational cancer treatments that are capable of inducing JNK phosphorylation and induce programmed cell death. It also identified genes as target for anti-cancer drug development and enhancement of the chemotherapeutic drug effect for the treatment of cancer. This invention points to a novel method and principle for a new avenue of developing more efficient and low or non cytotoxic cancer treatment.